Cristine Cazeiro1, Cristina Silva2, Susana Mayer2, Vanessa Mariany2, Claire Elizabeth Wainwright3, Linjie Zhang4,2,5. 1. Postgraduate Program in Public Health. 2. Faculty of Medicine, Federal University of Rio Grande, Rio Grande, Brazil; and. 3. Department of Respiratory and Sleep Medicine, Lady Cilento Children's Hospital and School of Medicine, The University of Queensland, Brisbane, Australia. 4. Postgraduate Program in Public Health, lzhang@furg.br. 5. Postgraduate Program in Health Science, and.
Abstract
CONTEXT: Inhaled corticosteroids (ICS) are associated with an increased risk of pneumonia in adult patients with chronic obstructive pulmonary disease. OBJECTIVE: To assess the association between ICS use and risk of pneumonia and other respiratory infections in children with asthma. DATA SOURCES: We searched PubMed from inception until May 2015. We also searched clinicaltrials.gov and databases of pharmaceutical manufacturers. STUDY SELECTION: We selected randomized trials that compared ICS with placebo for at least 4 weeks in children with asthma. DATA EXTRACTION: We included 39 trials, of which 31 trials with 11 615 patients contributed data to meta-analyses. RESULTS: The incidence of pneumonia was 0.58% (44/7465) in the ICS group and 1.51% (63/4150) in the placebo group. The meta-analysis of 9 trials that revealed at least 1 event of pneumonia revealed a reduced risk of pneumonia in patients taking ICS (risk ratio [RR]: 0.65; 95% confidence interval [CI]: 0.44 to 0.94). Using risk difference as effect measure, the meta-analysis including all 31 trials revealed no significant difference in the risk of pneumonia between the ICS and placebo groups (risk difference: -0.1%; 95% CI: -0.3% to 0.2%). No significant association was found between ICS and risk of pharyngitis (RR: 1.01; 95% CI: 0.87 to 1.18), otitis media (RR: 1.07; 95% CI: 0.83 to 1.37), and sinusitis (RR: 0.89; 95% CI: 0.76 to 1.05). LIMITATIONS: Lack of clearly defined criteria for respiratory infections and possible publication bias. CONCLUSIONS: Regular use of ICS may not increase the risk of pneumonia or other respiratory infections in children with asthma.
CONTEXT: Inhaled corticosteroids (ICS) are associated with an increased risk of pneumonia in adult patients with chronic obstructive pulmonary disease. OBJECTIVE: To assess the association between ICS use and risk of pneumonia and other respiratory infections in children with asthma. DATA SOURCES: We searched PubMed from inception until May 2015. We also searched clinicaltrials.gov and databases of pharmaceutical manufacturers. STUDY SELECTION: We selected randomized trials that compared ICS with placebo for at least 4 weeks in children with asthma. DATA EXTRACTION: We included 39 trials, of which 31 trials with 11 615 patients contributed data to meta-analyses. RESULTS: The incidence of pneumonia was 0.58% (44/7465) in the ICS group and 1.51% (63/4150) in the placebo group. The meta-analysis of 9 trials that revealed at least 1 event of pneumonia revealed a reduced risk of pneumonia in patients taking ICS (risk ratio [RR]: 0.65; 95% confidence interval [CI]: 0.44 to 0.94). Using risk difference as effect measure, the meta-analysis including all 31 trials revealed no significant difference in the risk of pneumonia between the ICS and placebo groups (risk difference: -0.1%; 95% CI: -0.3% to 0.2%). No significant association was found between ICS and risk of pharyngitis (RR: 1.01; 95% CI: 0.87 to 1.18), otitis media (RR: 1.07; 95% CI: 0.83 to 1.37), and sinusitis (RR: 0.89; 95% CI: 0.76 to 1.05). LIMITATIONS: Lack of clearly defined criteria for respiratory infections and possible publication bias. CONCLUSIONS: Regular use of ICS may not increase the risk of pneumonia or other respiratory infections in children with asthma.
Authors: Aran Singanayagam; Nicholas Glanville; Leah Cuthbertson; Nathan W Bartlett; Lydia J Finney; Elena Turek; Eteri Bakhsoliani; Maria Adelaide Calderazzo; Maria-Belen Trujillo-Torralbo; Joseph Footitt; Phillip L James; Peter Fenwick; Samuel V Kemp; Thomas B Clarke; Jadwiga A Wedzicha; Michael R Edwards; Miriam Moffatt; William O Cookson; Patrick Mallia; Sebastian L Johnston Journal: Sci Transl Med Date: 2019-08-28 Impact factor: 17.956
Authors: Min Hye Kim; Chin Kook Rhee; Ji Su Shim; So Young Park; Kwang Ha Yoo; Bo Yeon Kim; Hye Won Bae; Yun Su Sim; Jung Hyun Chang; Young Joo Cho; Jin Hwa Lee Journal: Allergy Asthma Immunol Res Date: 2019-11 Impact factor: 5.764
Authors: Helen A Brough; Omer Kalayci; Anna Sediva; Eva Untersmayr; Daniel Munblit; Pablo Rodriguez Del Rio; Marta Vazquez-Ortiz; Stefania Arasi; Montserrat Alvaro-Lozano; Sophia Tsabouri; Elena Galli; Burcin Beken; Philippe A Eigenmann Journal: Pediatr Allergy Immunol Date: 2020-05-31 Impact factor: 5.464